Short answer
Alnylam Pharmaceuticals (ALNY) filed its Q2 2025 10-Q quarterly report on Jul 31, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $774M (up 17.3% year over year) with net income of −$66M.
Q2 2025 key financials · XBRL
- Revenue
- $774M
- +17.3% YoY · +30.2% QoQ
- Net income
- −$66M
- −292.4% YoY · −15.3% QoQ
- Operating margin
- -2.1%
- EPS (diluted)
- −$0.51
- −264.3% YoY · −15.9% QoQ
Source: XBRL data from the Alnylam Pharmaceuticals (ALNY) Q2 2025 10-Q on SEC EDGAR. USD.
Alnylam Pharmaceuticals Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash, cash equivalents, marketable securities sufficient for next 12 months from filing date
- Potential need for significant additional funds earlier than expected
- Funding required for commercialization, development, clinical trials, manufacturing, and new product candidates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alnylam Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.